157 related articles for article (PubMed ID: 24837398)
1. Access to oral osteoporosis drugs among female Medicare Part D beneficiaries.
Lin CW; Karaca-Mandic P; McCullough JS; Weaver L
Womens Health Issues; 2014; 24(4):e435-45. PubMed ID: 24837398
[TBL] [Abstract][Full Text] [Related]
2. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
3. Minimizing out-of-pocket prescription drug costs for Medicare beneficiaries: not just 'a drop in the bucket'.
Patel RA; Vo KA; Chu T; Wang K; Lu S; Woelfel JA; Carr-Lopez SM; Galal SM
J Am Pharm Assoc (2003); 2014; 54(6):604-9. PubMed ID: 25379981
[TBL] [Abstract][Full Text] [Related]
4. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
[TBL] [Abstract][Full Text] [Related]
5. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
6. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
Blumberg DM; Prager AJ; Liebmann JM
JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
[TBL] [Abstract][Full Text] [Related]
7. Effects of an out-of-pocket maximum in Medicare Part D.
Parasrampuria S; Anderson GF
Am J Manag Care; 2022 Feb; 28(2):e55-e62. PubMed ID: 35139297
[TBL] [Abstract][Full Text] [Related]
8. Out-of-pocket costs and oral cancer medication discontinuation in the elderly.
Kaisaeng N; Harpe SE; Carroll NV
J Manag Care Spec Pharm; 2014 Jul; 20(7):669-75. PubMed ID: 24967520
[TBL] [Abstract][Full Text] [Related]
9. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
Odouard IC; Anderson GF; Alexander GC; Ballreich J
J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
[TBL] [Abstract][Full Text] [Related]
10. Out-of-Pocket Costs for Long-Acting Injectable and Oral Antipsychotics Among Medicare Patients With Schizophrenia.
Doshi JA; Li P; Geng Z; Seo S; Patel C; Benson C
Psychiatr Serv; 2024 Apr; 75(4):333-341. PubMed ID: 37960866
[TBL] [Abstract][Full Text] [Related]
11. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
[TBL] [Abstract][Full Text] [Related]
12. Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer.
Narang AK; Nicholas LH
JAMA Oncol; 2017 Jun; 3(6):757-765. PubMed ID: 27893028
[TBL] [Abstract][Full Text] [Related]
13. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
[TBL] [Abstract][Full Text] [Related]
14. Impact of Medicare Part D for Medicare-age adults with arthritis: prescription use, prescription expenditures, and medical spending from 2005 to 2008.
Cheng LI; Rascati KL
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1423-9. PubMed ID: 22508663
[TBL] [Abstract][Full Text] [Related]
15. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
Olszewski AJ; Dusetzina SB; Eaton CB; Davidoff AJ; Trivedi AN
J Clin Oncol; 2017 Oct; 35(29):3306-3314. PubMed ID: 28541791
[TBL] [Abstract][Full Text] [Related]
16. Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage.
Siris ES; Yu J; Bognar K; DeKoven M; Shrestha A; Romley JA; Modi A
Clin Interv Aging; 2015; 10():1813-24. PubMed ID: 26604724
[TBL] [Abstract][Full Text] [Related]
17. Association of Medicare Part D medication out-of-pocket costs with utilization of statin medications.
Karaca-Mandic P; Swenson T; Abraham JM; Kane RL
Health Serv Res; 2013 Aug; 48(4):1311-33. PubMed ID: 23278369
[TBL] [Abstract][Full Text] [Related]
18. Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act.
Spivey CA; Wang J; Qiao Y; Shih YT; Wan JY; Kuhle J; Dagogo-Jack S; Cushman WC; Chisholm-Burns M
J Manag Care Spec Pharm; 2018 Feb; 24(2):97-107. PubMed ID: 29384031
[TBL] [Abstract][Full Text] [Related]
19. Has Medicare Part D reduced racial/ethnic disparities in prescription drug use and spending?
Mahmoudi E; Jensen GA
Health Serv Res; 2014 Apr; 49(2):502-25. PubMed ID: 24102408
[TBL] [Abstract][Full Text] [Related]
20. Effects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more?
Mott DA; Thorpe JM; Thorpe CT; Kreling DH; Gadkari AS
Res Social Adm Pharm; 2010 Jun; 6(2):90-9. PubMed ID: 20511108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
